Related Experiment Videos
Acute multiple sclerosis with contrast-enhancing plaques
Abstract:
In a case of clinically fulminant multiple sclerosis (MS), contrast-enhancing lesions were visible by computerized axial tomography (CT). The patient died less than three weeks after the study, making neuropathologic correlation possible. It appears that areas of contrast enhancement correlate in acute MS with early demyelinative lesions, and enhancement is related to breakdown of the blood-brain barrier. That such a disturbance is important in the pathogenesis of demyelination in MS has been suggested by other data as well. The characteristic CT findings of MS must therefore include enhancing lesions that reflect disease activity and that may be the only CT abnormality.
Insights
Contrast-enhancing lesions on CT scans indicate active demyelination in acute multiple sclerosis (MS). These findings reveal early blood-brain barrier breakdown, crucial for understanding MS pathogenesis.
Area of Science:
- Neurology
- Radiology
- Pathology
Background:
- Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
- Understanding the early pathological changes in MS is crucial for diagnosis and treatment.
- Computerized axial tomography (CT) is a key imaging modality in neurological assessment.
Observation:
- A case of clinically fulminant multiple sclerosis (MS) was studied.
- Contrast-enhancing lesions were identified using CT imaging.
- Neuropathologic correlation was possible due to the patient's rapid decline and death.
Findings:
- Contrast enhancement on CT scans correlates with early demyelinative lesions in acute MS.
- Lesion enhancement is directly related to the breakdown of the blood-brain barrier.
- These enhancing lesions may represent the sole abnormality detected by CT.
Implications:
- CT-visible enhancing lesions are indicative of active disease in multiple sclerosis.
- The findings support the role of blood-brain barrier disruption in MS pathogenesis.
- Identifying these lesions is vital for characterizing disease activity and progression.